Merck (NYSE:MRK) is one of those very few companies that has not only reported strong financial performance in Q1 2017 but also raised its 2017 revenue and EPS guidance.
And all this was achieved by the company in a quarter where it had to face loss of exclusivities worth $700 million. Clawing back from such a challenging situation requires a pharmaceutical company to have both top-notch products as well as a focused commercial strategy.
Based on its fundamentals, I believe there is significant upside potential in Merck. And Keytruda has become the number one reason for investing in this company. In this article, I will explain why Keytruda can be a solid reason for favoring Merck as an attractive investment opportunity.
